StellaPharma Inc, a company involved in over-the-counter, customer-focused health products, spanning three generations in the pharmaceutical industry, has signed a contract with G2B Pharma.
It was reported yesterday that the contract has been signed to acquire the assets of G2B Pharma including IP related to a dry powder nasal formulation of epinephrine being developed for anaphylaxis. If approved by US FDA, nasally delivered dry powder epinephrine could provide a required alternative to epinephrine auto-injectors.
G2B Pharma CEO and epinephrine dry powder spray inventor Dr Nigel Fleming said, 'We are excited to see this important product move forward with the StellaPharma team and are eager to contribute to its development and commercial success.'
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data